Total Payments
$2,831
2023 Payments
$261.16
Companies
43
Transactions
152
Medicare Patients
977
Medicare Billing
$144,872
Payment Breakdown by Category
Food & Beverage$2,675 (94.5%)
Education$156.16 (5.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,675 | 148 | 94.5% |
| Education | $156.16 | 4 | 5.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $332.02 | 18 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $189.49 | 12 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $150.34 | 9 | $0 (2023) |
| Incyte Corporation | $138.18 | 4 | $0 (2021) |
| GENZYME CORPORATION | $137.26 | 6 | $0 (2022) |
| Seagen Inc. | $135.94 | 7 | $0 (2022) |
| Merck Sharp & Dohme LLC | $135.00 | 8 | $0 (2023) |
| Celgene Corporation | $129.81 | 7 | $0 (2023) |
| Amgen Inc. | $128.66 | 9 | $0 (2022) |
| GlaxoSmithKline, LLC. | $104.78 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $261.16 | 13 | Mirati Therapeutics, Inc. ($45.63) |
| 2022 | $1,554 | 79 | Novartis Pharmaceuticals Corporation ($277.43) |
| 2021 | $886.33 | 52 | Incyte Corporation ($138.18) |
| 2020 | $44.39 | 3 | AstraZeneca Pharmaceuticals LP ($20.93) |
| 2019 | $61.09 | 4 | Janssen Biotech, Inc. ($34.95) |
| 2018 | $24.13 | 1 | AbbVie, Inc. ($24.13) |
All Payment Transactions
152 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/01/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $24.63 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 02/15/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: ONCOLOGY | ||||||
| 02/14/2023 | Genentech USA, Inc. | Perjeta (Biological), Phesgo | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: BioOncology | ||||||
| 02/08/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: ONC | ||||||
| 01/26/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: BioOncology | ||||||
| 01/23/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: HORMONE THERAPY | ||||||
| 01/17/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $28.52 | General |
| Category: ONCOLOGY | ||||||
| 01/11/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.67 | General |
| Category: Hematology | ||||||
| 01/10/2023 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Diagnostic Imaging | ||||||
| 01/10/2023 | PFIZER INC. | XTANDI (Drug), ORGOVYX, COMIRNATY | Food and Beverage | In-kind items and services | $19.92 | General |
| Category: ONCOLOGY | ||||||
| 01/04/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $19.20 | General |
| Category: Oncology | ||||||
| 01/03/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: ONCOLOGY | ||||||
| 12/22/2022 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug), TASIGNA | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: ONCOLOGY | ||||||
| 12/21/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.02 | General |
| Category: Oncology | ||||||
| 12/13/2022 | Seagen Inc. | ADCETRIS (Biological) | Food and Beverage | In-kind items and services | $9.54 | General |
| Category: Oncology | ||||||
| 12/12/2022 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $14.30 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2022 | Genentech USA, Inc. | VENCLEXTA (Biological) | Food and Beverage | In-kind items and services | $19.90 | General |
| Category: BioOncology | ||||||
| 12/01/2022 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: Oncology | ||||||
| 11/28/2022 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: Oncology | ||||||
| 11/15/2022 | Seagen Inc. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $20.27 | General |
| Category: Oncology | ||||||
| 11/08/2022 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: ONC | ||||||
| 11/07/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $17.13 | General |
| Category: Oncology | ||||||
| 10/31/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 329 | 408 | $149,527 | $45,871 |
| 2022 | 5 | 237 | 516 | $112,966 | $44,707 |
| 2021 | 5 | 240 | 535 | $111,023 | $44,380 |
| 2020 | 4 | 171 | 217 | $29,579 | $9,914 |
Total Patients
977
Total Services
1,676
Medicare Billing
$144,872
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 197 | 223 | $67,380 | $20,217 | 30.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 91 | 144 | $60,216 | $19,186 | 31.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $16,647 | $5,145 | 30.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 13 | 13 | $5,284 | $1,323 | 25.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 43 | 201 | $49,245 | $21,467 | 43.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 124 | 243 | $44,226 | $16,237 | 36.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 30 | 30 | $10,470 | $4,163 | 39.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 25 | 25 | $6,900 | $2,109 | 30.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 15 | 17 | $2,125 | $729.92 | 34.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 147 | 330 | $60,242 | $22,419 | 37.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 40 | 149 | $36,505 | $16,485 | 45.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 19 | 19 | $6,631 | $2,708 | 40.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 20 | 20 | $5,520 | $1,976 | 35.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 14 | 17 | $2,125 | $791.40 | 37.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 87 | 128 | $21,196 | $7,918 | 37.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 15 | 18 | $4,130 | $1,591 | 38.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2020 | 32 | 33 | $1,155 | $244.79 | 21.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 11 | $2,585 | $82.97 | 3.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 26 | 27 | $513.00 | $77.05 | 15.0% |
About Dr. M. Daud Nawabi, MD
Dr. M. Daud Nawabi, MD is a Hematology & Oncology healthcare provider based in Orangeburg, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275554594.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. M. Daud Nawabi, MD has received a total of $2,831 in payments from pharmaceutical and medical device companies, with $261.16 received in 2023. These payments were reported across 152 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($2,675).
As a Medicare-enrolled provider, Nawabi has provided services to 977 Medicare beneficiaries, totaling 1,676 services with total Medicare billing of $144,872. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Orangeburg, SC
- Active Since 07/21/2006
- Last Updated 01/27/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1275554594
Products in Payments
- OPDIVO (Biological) $138.59
- KEYTRUDA (Biological) $135.00
- KISQALI (Drug) $123.65
- Pomalyst (Drug) $112.76
- PROMACTA (Drug) $97.98
- LONSURF (Drug) $93.81
- TUKYSA (Drug) $85.19
- TAGRISSO (Drug) $76.93
- Trodelvy (Drug) $74.07
- ZEJULA (Drug) $66.50
- LIBTAYO (Biological) $65.73
- ORGOVYX (Drug) $63.46
- Kyprolis (Drug) $61.38
- SCEMBLIX (Drug) $58.64
- JEVTANA (Drug) $57.71
- IMBRUVICA (Drug) $52.76
- KRAZATI (Drug) $45.63
- clonoSEQ (Device) $43.71
- PADCEV (Biological) $41.21
- Xospata (Drug) $39.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.